SLC 0111

Drug Profile

SLC 0111

Alternative Names: SLC-0111; WBI-5111

Latest Information Update: 21 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SignalChem Lifesciences
  • Developer SignalChem Lifesciences; Welichem Biotech
  • Class Cytostatics; Small molecules
  • Mechanism of Action Carbonic anhydrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 18 Jul 2016 SignalChem Lifesciences and Welichem Biotech agree to co-develop SLC 0111 (SignalChem Lifesciences pipeline, July 2016)
  • 14 Apr 2016 Pharmacodynamics data from a preclinical trial in Pancreatic ductal adenocarcinoma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 14 Apr 2016 SignalChem Lifesciences plans a phase Ib trial in Pancreatic ductal adenocarcinoma (Metastatic disease, Late-stage disease, Combination therapy) in Canada (PO) (NCT03450018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top